Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.
from Medical Xpress - latest medical and health news stories https://ift.tt/mPY3U0l
